Deepull closes €50 million funding round

Cuatrecasas has advised Deepull Diagnostics, S.L., (“Deepull”) on a €50 million Series C funding round.

Deepull, a medical diagnostics company developing culture-free solutions, will use the funds to finalize clinical validations and advance the regulatory approval process of its UllCORE diagnostic system. Last December, this system received Breakthrough Device Designation from the U.S. Food and Drug Administration. UllCORE is a fully automated system—without manual intervention—that uses cutting edge molecular techniques to extract and detect microbial DNA directly from blood. The test covers 95% of sepsis-causing pathogens, including bacteria and fungi, as well as antibiotic resistance genes, providing results in about one hour.

The funding from this new round is a crucial milestone for Deepull as it moves towards completing the clinical studies of its diagnostic system. The aim is to offer a transformative diagnostic solution to healthcare providers and patients worldwide.

Elena Cuatrecasas, who led the transaction’s advisory team in collaboration with lawyers Amador Rodríguez, Georgina Bofill, María Palos and Nuria Lafuente, said: “It is a privilege to have accompanied Deepull and its partners from the beginning of this exciting project to the successful achievement of this important milestone: the Series C funding round. This enables the company to take on new challenges and boost its growth, and is another example of the dynamism of the life sciences industry in our region”.